[A24-47] Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V
Last updated 01.08.2024
Project no.:
A24-47
Commission:
Commission awarded on 25.04.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with non-small cell lung cancer who are at high risk of recurrence following complete resection and platinum-based chemotherapy; adjuvant treatment
Hint of lesser benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A24-47